Inegy

Simvastatin and ezetimibe, the active ingredients in Inegy, are a HMG‑CoA reductase inhibitor and a cholesterol absorption inhibitor presented as oral tablets for oral use. They are indicated for lowering elevated cholesterol and triglyceride levels in adults with hypercholesterolemia or mixed dyslipidemia.

GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inegy is used to manage lipid disorders by targeting cholesterol synthesis and absorption pathways.

Hypercholesterolemia: lowers low‑density lipoprotein cholesterol (LDL‑C) and total cholesterol levels. Mixed dyslipidemia: improves overall lipid profile, reducing LDL‑C and triglycerides while modestly raising HDL‑C. Familial heterozygous hypercholesterolemia: provides additional LDL‑C reduction when diet and lifestyle alone are insufficient.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose stools occurring intermittently. - Nausea: feeling of queasiness. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Acute liver injury: marked elevation of hepatic enzymes or jaundice. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Stevens‑Johnson syndrome: severe skin and mucous membrane disorder.

Patients should be monitored for safety concerns before and during therapy.

Liver function monitoring: assess baseline transaminases and repeat periodically. Muscle symptom vigilance: educate patients to report unexplained muscle pain or weakness. Drug interaction awareness: avoid concomitant use of strong CYP3A4 inhibitors. Pregnancy and lactation: use only if potential benefit justifies potential risk. Renal impairment considerations: dose adjustment may be required in severe renal dysfunction. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Inegy may interact with other medicines, requiring caution.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can increase simvastatin exposure. - Gemfibrozil: markedly raises risk of myopathy and rhabdomyolysis. - Cyclosporine: elevates both simvastatin and ezetimibe plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Amiodarone: can increase simvastatin concentrations, necessitating dose review.